Cytokinetics Inc (CYTK)
Debt-to-equity ratio
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Long-term debt | US$ in thousands | — | — | — | — | — |
| Total stockholders’ equity | US$ in thousands | -135,372 | -386,323 | -107,900 | 243,863 | 113,383 |
| Debt-to-equity ratio | — | — | — | 0.00 | 0.00 |
December 31, 2024 calculation
Debt-to-equity ratio = Long-term debt ÷ Total stockholders’ equity
= $—K ÷ $-135,372K
= —
The debt-to-equity ratio for Cytokinetics Inc shows a consistent trend of 0.00 from December 31, 2020, to December 31, 2021, indicating that the company has not utilized debt to finance its operations relative to its equity during these periods. The data further reveals that there is no specific debt or equity information available for the subsequent years (December 31, 2022, 2023, and 2024), represented by "—". Without additional data for these years, it is difficult to assess the company's leverage position or its capital structure beyond 2021. Overall, the stable 0.00 ratio in the earlier years suggests that the company may have been relying more on equity financing or maintaining a conservative debt strategy.
Peer comparison
Dec 31, 2024